Hable con su médico o equipo de atención
Imprima esta página con detalles sobre el estudio o envíela por correo electrónico a su médico para analizar el estudio clínico durante su próxima visita.
Propósito del estudio
El objetivo de este estudio es averiguar si las personas que reciben V940 y pembrolizumab después de la cirugía están libres de cáncer durante más tiempo que las personas que reciben placebo y pembrolizumab. Los investigadores desean saber si la administración de V940 y pembrolizumab después de la cirugía puede ayudar a prevenir la reaparición del cáncer en personas con cáncer de pulmón de células no pequeñas (NSCLC) cuyos tumores no respondieron completamente al tratamiento antes de la cirugía (tratamiento neoadyuvante).
 |
nÚmero nacional de referencia del estudio | NCT06623422 |
 |
Afecciones |
Carcinoma de pulmón de células no pequeñas
|
 |
Rango etario | 18+ |
 |
Sexo | Todos |
 |
Fase actual del estudio | 3 |
 |
Fechas de inicio y finalización del estudio |
10-21-2024 01-26-2038 |
Acerca del estudio
Elegibilidad
Solo un proveedor de atención médica calificado puede determinar si usted es elegible para participar en un estudio clínico. Sin embargo, esta información puede ser útil para iniciar una conversación con su médico.
Afecciones
Carcinoma de pulmón de células no pequeñas
Fase 3
En los estudios de fase 3, los investigadores intentan averiguar si un tratamiento funciona en una gran cantidad de personas, generalmente alrededor de 1000 a 5000 participantes que tienen la afección médica que pretende tratar el tratamiento. En los estudios con vacunas, los participantes pueden estar sanos o tener enfermedades o afecciones. Los estudios de fase 3 pueden realizarse en el consultorio de un médico, en una clínica o en un hospital.
Ubicaciones del estudio (0)
Las ubicaciones mostradas pueden haber cambiado en algunos casos. Llame al número que figura en los resultados de la ubicación para confirmar el centro del estudio más cercano. Hable con un miembro del centro del estudio para obtener más información
Frequently Asked Questions
About the Study
Before you agree to participate, the study team will review all aspects of the research study with you. If you decide to take part, you will be given a document called an Informed Consent Form that provides, in writing, the research study s purpose, assessments, procedures, potential benefits
and risks, and precautions. You will have the opportunity to ask questions and decide if participating is right for you.
Privacy, Stopping Participation, Costs, and Permission
The study team respects and protects your privacy and will not share your information except as required by law and will store your personal
information with codes that do not identify you. The Informed Consent Form (completed by you prior to participation) will provide more
information about how your privacy will be maintained.
Yes, your participation in the research study is entirely voluntary and you may withdraw for any reason, at any time. If you do decide to withdraw
early, you will be asked to notify the study team before doing so. You will also be asked to return to the study site at least once to complete a final
visit and return any unused study drugs.
No, you will receive the study drugs at no cost. You will also get all study related medical tests at no cost.
No, your doctor does not have to give permission for you to participate. However, either you or the study doctor, with your permission, may
contact your personal doctor to discuss your participation before you begin and keep your doctor up to date about your progress.
About Research Studies
A research study, also known as a clinical trial, tries to answer questions about how medicines work in the people who take them. Researchers run
studies to test whether an investigational study drug is safe and effective. These research studies may help doctors find new ways to help prevent,
detect, or treat health problems.
Participant safety is the priority. There are rules in place to help protect the rights, safety, and well being of people who volunteer for research
studies. These rules are put in place to make sure research studies follow strict scientific and ethical guidelines.
Before a research study can begin, a review board or ethics committee must review the research study. In the US, this group is called an IRB or
Institutional Review Board. An IRB is made up of doctors, scientists, and other members of the community.
Only people who meet all eligibility criteria for a research study may take part. The study team at the site you select will review your medical
history and current medical status against the eligibility criteria. They will determine whether you are eligible to participate. You may also be asked
to provide information from your medical records to help the study team determine whether you may be eligible.
An investigational study drug is a drug that hasn t yet been approved for use in the general public. In order to be approved, the investigational
study drug must be tested in research studies to see if it is safe and effective for treating the target disease in certain groups of people.
If you are eligible and choose to participate, the study staff will be available to answer any questions you may have.
For more answers to your questions visit: https://www.merckclinicaltrials.com/faq/